Four patients with genetic cholinesterase abnormalities were studied with electromyography after being given suxamethonium 0.1 mg/kg. An abnormal homozygous patient was paralysed for 17 minutes. The duration of response in heterozygous patients was 2-4 minutes, being shorter when cholinesterase activity levels were near normal.
INTRODUCTION
Suxamethonium is normally rapidly broken down by plasma cholinesterase. The usual dose of 1.0 mg/kg paralyses most patients for about [3] [4] [5] minutes. There are some in whom the plasma cholinesterase is inactivated by drugs, is reduced in amount, as in pregnancy and neonates, or is less active due to genetic variants of the enzyme. 1 In these patients the duration of action is prolonged. Dose and age also influence the onset and duration of action. 2 This paper reports the electromyographic response to suxamethonium 0.1 mg/kg in four children with genetic variants of cholinesterase.
METHODS
Four patients known to have genetic variants of cholinesterase, or with a family history, were studied electromyographically with suxamethonium 0.1 mg/kg. The degree of paralysis and duration of action were measured. Stimulating electrodes were placed over the median nerve at the wrist, the recording electrodes were placed over opponens pollicis and the dorsal aspect of the thumb and the neutral electrode on the forearm. 4 Having set the gain so that the integrated electromyographic twitch height (lEMG) was 100%, a single supramaximal stimulus was administered every ten seconds. Blood for measuring dibucaine number (ON) and cholinesterase (ChE) levels was taken at the same time. These tests were carried out in the Biochemistry Department, Royal Melbourne Hospital. RESULTS Figure 1 shows the individual IEMG responses to a small dose of suxamethonium (0.1 mg/kg), the dibucaine and fluoride numbers and cholinesterase activity of patients with abnormal cholinesterase. The homozygous patient had the most profound response. The heterozygote with normal cholinesterase activity had the shortest response.
The normal values are shown for comparison with the mean EMG response from a study of 68 children. 2 ED95 values were derived from measurements made on the IEMG recordings in Figure 1 and normal dose response curves for suxamethonium for children between 1 and 10 years of age. 2 
DISCUSSION
Three heterozygous and one homozygous patient for abnormal cholinesterase were studied using suxamethonium 0.1 mg/kg. Although the heterozygotes had dibucaine numbers ranging from 48-65, their cholinesterase activities varied from 626 to 1431 units/I. The patient with 1431 unitll ChE activity developed about 80% paralysis which lasted about 2 minutes, while the other two patients developed over 90% paralysis which recovered to 50% by about 4 minutes. This is comparable to the duration following 1 mg/kg in normal children. The homozygote reached 92% depression, but recovery to 50% took 17 minutes --four times the mean for children under 11 years receiving 1 mg/kg. This would extrapolate to nearly 3 hours if the child had been given 1.0 mg/kg and other breakdown and elimination pathways were not available.
Cass, Doolan and Gutteridge 3 studied one homozygous adult patient on several occasions giving different doses between 0.05 and 0.1 mg/kg. They established an ED95 of70 Ilg/kg and a slope of 5. Smith et al. 4 did a cumulative dose response study on a homozygous (EaEf) woman and reported an ED95 of621lglkgand a slope of8. These are 0.22 and 0.2 times the normal adult ED95 determined by the same authors.
Measuring the ED95 only relates dose to the level of paralysis reached, while the duration of paralysis is more important clinically. A test dose of 0.1 mg/kg will not tend to cause an inconveniently long period of paralysis in a homozygous patient (15-20 minutes), while it will only provide 2-4 minutes paralysis in a heterozygous patient. If normal doses of 1.0 mg/kg are used, periods of apnoea up to 15-30 minutes might be expected in heterozygotes and up to 3 hours in homozygote patients.
Cherala, Eddie and Sechzer 5 reported that an 'atypical mother' had DN 24. At delivery she had no measurable ChE activity, but this had recovered to 490 units/l 3 months later. The newborn infant had DN 20 and ChE activity of 410 units/l which rose to 910 units/l at 3 months. The case shows that the dibucaine numbers remain the same but that cholinesterase activity can alter, presumably altering the duration of paralysis should suxamethonium be given.
When genetic cholinesterase abnormalities are found, patients are usually given a card warning of their sensitivity to suxamethonium. The Danish Cholinesterase Research unit issues cards to all patients with abnormal ChE genes 6 while Whitaker l in England suggests warning cards be given only to people with abnormal ChE genes who are homozygous or are heterozygous with less than 50% normal cholinesterase activity. It can be seen from our heterozygous patient with normal cholinesterase activity that recovery was rapid after suxamethonium 0.1 mg/kg and that very prolonged apnoea would be unlikely. In most heterozygous patients the prolongation of apnoea will cause the anaesthetist little inconvenience, unless the operative procedure is very short. Whitaker's suggestion therefore seems to be a useful practical approach.
